Amivantamab联合Lazertinib治疗非典型EGFR突变晚期NSCLC:CHRYSALIS-2结果
CHRYSALIS-2 C队列纳入105例非典型EGFR突变(G719X、S768I、L861Q等)晚期NSCLC患者,接受Amivantamab联合Lazertinib治疗。总体客观缓解率52%(95%CI 42-62),中位缓解持续时间14.1个月,中位无进展生存期11.1个月,安全性可控。初治患者ORR 57%,中位PFS 19.5个月。
要点
- 非典型EGFR突变晚期NSCLC中,Amivantamab联合Lazertinib总体ORR达52%,中位PFS 11.1个月。
- 初治患者ORR 57%,中位PFS 19.5个月,中位DoR 20.7个月。
- 不良事件以1-2级为主,与此前研究一致,未见新安全信号。
核心结论
- 在非典型EGFR突变晚期NSCLC患者中,Amivantamab联合Lazertinib显示出有临床意义的抗肿瘤活性,且无新的安全信号。
研究设计与样本
- CHRYSALIS-2研究C队列纳入携带非典型EGFR突变(G719X、S768I、L861Q等)且既往治疗线数≤2的晚期NSCLC患者,共105例接受Amivantamab联合Lazertinib治疗。
- 给药方案为Amivantamab 1,050 mg(体重≥80 kg者1,400 mg)静脉注射,前4周每周一次,之后每2周一次,联合Lazertinib 240 mg口服每日一次。
- 主要终点为研究者评估的客观缓解率(ORR)。
主要发现
- 总体人群(中位随访16.1个月)ORR为52%(95%CI 42-62),中位缓解持续时间(mDoR)为14.1个月(95%CI 9.5-26.2),中位无进展生存期(mPFS)为11.1个月(95%CI 7.8-17.8),中位总生存期(mOS)不可估计(NE;95%CI 22.8-NE)。
- 初治患者ORR为57%(95%CI 42-71),mPFS为19.5个月(95%CI 11.2-NE),mDoR为20.7个月(95%CI 9.9-NE),mOS为NE(95%CI 26.3-NE)。
- 单一或复合EGFR突变对ORR无重大影响;P-loop和αC-helix压缩型、古典样型及T790M样突变患者的ORR分别为45%(n=38)、64%(n=14)和67%(n=3)。
- 不良事件与此前研究一致,主要为1级和2级。
关键数值与推荐
- 总体ORR 52%(95%CI 42-62),mDoR 14.1个月(95%CI 9.5-26.2),mPFS 11.1个月(95%CI 7.8-17.8)。
- 初治患者ORR 57%(95%CI 42-71),mPFS 19.5个月(95%CI 11.2-NE),mDoR 20.7个月(95%CI 9.9-NE)。
- P-loop和αC-helix压缩型突变ORR 45%(n=38),古典样型64%(n=14),T790M样型67%(n=3)。
临床怎么用
- 对于携带非典型EGFR突变(如G719X、S768I、L861Q)的晚期NSCLC患者,Amivantamab联合Lazertinib可作为潜在治疗选择,尤其在一线治疗时ORR和PFS数据更优。
- 治疗前应明确EGFR突变亚型,复合突变患者也可从该联合方案中获益。
- 治疗期间需监测不良事件,但整体安全性以1-2级为主,未见新安全信号。
局限性
- 本研究为单臂队列研究,缺乏随机对照,结论需进一步验证。
- 样本量有限(105例),部分突变亚型(如T790M样)例数较少(n=3),亚组分析结果需谨慎解读。
- 中位总生存期数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited. PATIENTS AND METHODS: CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical EGFR mutations (G719X, S768I, L861Q, etc) and ≤2 previous lines of therapy. Participants were treatment-naïve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if ≥80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR). RESULTS: As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound EGFR mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively. CONCLUSION: In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
引用
- Tomasini P, Wang Y, Li Y, et al. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2025. PMID: 41325571. doi:10.1200/JCO-24-02835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。